唾液腺恶性肿瘤的化疗:Meta 分析和系统综述。

IF 2.6 2区 工程技术 Q2 MECHANICS
Multibody System Dynamics Pub Date : 2024-02-01 Epub Date: 2023-08-11 DOI:10.1007/s12070-023-04104-6
Kritant Bhushan, Mansi Luthra Sharma, Deepak Kumar Gupta
{"title":"唾液腺恶性肿瘤的化疗:Meta 分析和系统综述。","authors":"Kritant Bhushan, Mansi Luthra Sharma, Deepak Kumar Gupta","doi":"10.1007/s12070-023-04104-6","DOIUrl":null,"url":null,"abstract":"<p><p> The primary form of treatment for salivary gland cancer is surgical resection. Radiation therapy is used as adjuvant therapy in cases of aggressive tumours, currently patients with recurrent or metastatic cancer who are not suitable for surgery or radiation are most often treated with chemotherapy. PRISMA guidelines for systematic reviews were followed to evaluate salivary gland malignancies involving cytotoxic chemotherapy and biologic agents. An electronic literature search of Medline, PubMed, Scopus, etc. was performed and relevant articles were selected based on the inclusion criteria. Cytotoxic chemotherapies and biologic drugs such as anti HER - 2, anti-EGFR and anti-C-Kit are used to treat salivary gland cancer. Although most trials have respond poorly to standard chemotherapy with short durability and significant toxicity. Most of the research has focused on ACC and the use of combination therapy with cisplastin in conjunction with other treatments has been found to improve overall survival rate. Due to the limited patient population it was difficult to assess the efficacy of chemotherapy, which achieved very modest results. There are potential molecular targets such as HER2,NTRK and targeted treatments are becoming more popular. However to further explore potential treatment alternatives SGC patients should be enrolled in clinical trials.</p>","PeriodicalId":49792,"journal":{"name":"Multibody System Dynamics","volume":"31 1","pages":"123-129"},"PeriodicalIF":2.6000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908940/pdf/","citationCount":"0","resultStr":"{\"title\":\"<b>Chemotherapy for Salivary Gland Malignant Carcinoma : Meta-analysis and Systemic Review</b>.\",\"authors\":\"Kritant Bhushan, Mansi Luthra Sharma, Deepak Kumar Gupta\",\"doi\":\"10.1007/s12070-023-04104-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p> The primary form of treatment for salivary gland cancer is surgical resection. Radiation therapy is used as adjuvant therapy in cases of aggressive tumours, currently patients with recurrent or metastatic cancer who are not suitable for surgery or radiation are most often treated with chemotherapy. PRISMA guidelines for systematic reviews were followed to evaluate salivary gland malignancies involving cytotoxic chemotherapy and biologic agents. An electronic literature search of Medline, PubMed, Scopus, etc. was performed and relevant articles were selected based on the inclusion criteria. Cytotoxic chemotherapies and biologic drugs such as anti HER - 2, anti-EGFR and anti-C-Kit are used to treat salivary gland cancer. Although most trials have respond poorly to standard chemotherapy with short durability and significant toxicity. Most of the research has focused on ACC and the use of combination therapy with cisplastin in conjunction with other treatments has been found to improve overall survival rate. Due to the limited patient population it was difficult to assess the efficacy of chemotherapy, which achieved very modest results. There are potential molecular targets such as HER2,NTRK and targeted treatments are becoming more popular. However to further explore potential treatment alternatives SGC patients should be enrolled in clinical trials.</p>\",\"PeriodicalId\":49792,\"journal\":{\"name\":\"Multibody System Dynamics\",\"volume\":\"31 1\",\"pages\":\"123-129\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908940/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multibody System Dynamics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12070-023-04104-6\",\"RegionNum\":2,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MECHANICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multibody System Dynamics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12070-023-04104-6","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MECHANICS","Score":null,"Total":0}
引用次数: 0

摘要

唾液腺癌的主要治疗方式是手术切除。放射治疗用于侵袭性肿瘤的辅助治疗,目前不适合手术或放射治疗的复发性或转移性癌症患者多采用化疗。在评估涉及细胞毒性化疗和生物制剂的唾液腺恶性肿瘤时,我们遵循了系统性综述的 PRISMA 指南。我们在 Medline、PubMed、Scopus 等网站上进行了电子文献检索,并根据纳入标准筛选出相关文章。细胞毒性化疗药和生物制剂,如抗 HER - 2、抗EGFR 和抗 C-Kit 等,被用于治疗唾液腺肿瘤。虽然大多数试验对标准化疗的反应不佳,疗效不持久,毒性大。大多数研究都集中在 ACC 上,发现顺铂与其他疗法联合使用可提高总生存率。由于患者人数有限,很难评估化疗的疗效,化疗取得的效果也很一般。目前有一些潜在的分子靶点,如 HER2、NTRK,靶向治疗正变得越来越流行。不过,为了进一步探索潜在的替代治疗方法,SGC 患者应参加临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Chemotherapy for Salivary Gland Malignant Carcinoma : Meta-analysis and Systemic Review.

 The primary form of treatment for salivary gland cancer is surgical resection. Radiation therapy is used as adjuvant therapy in cases of aggressive tumours, currently patients with recurrent or metastatic cancer who are not suitable for surgery or radiation are most often treated with chemotherapy. PRISMA guidelines for systematic reviews were followed to evaluate salivary gland malignancies involving cytotoxic chemotherapy and biologic agents. An electronic literature search of Medline, PubMed, Scopus, etc. was performed and relevant articles were selected based on the inclusion criteria. Cytotoxic chemotherapies and biologic drugs such as anti HER - 2, anti-EGFR and anti-C-Kit are used to treat salivary gland cancer. Although most trials have respond poorly to standard chemotherapy with short durability and significant toxicity. Most of the research has focused on ACC and the use of combination therapy with cisplastin in conjunction with other treatments has been found to improve overall survival rate. Due to the limited patient population it was difficult to assess the efficacy of chemotherapy, which achieved very modest results. There are potential molecular targets such as HER2,NTRK and targeted treatments are becoming more popular. However to further explore potential treatment alternatives SGC patients should be enrolled in clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.00
自引率
17.60%
发文量
46
审稿时长
12 months
期刊介绍: The journal Multibody System Dynamics treats theoretical and computational methods in rigid and flexible multibody systems, their application, and the experimental procedures used to validate the theoretical foundations. The research reported addresses computational and experimental aspects and their application to classical and emerging fields in science and technology. Both development and application aspects of multibody dynamics are relevant, in particular in the fields of control, optimization, real-time simulation, parallel computation, workspace and path planning, reliability, and durability. The journal also publishes articles covering application fields such as vehicle dynamics, aerospace technology, robotics and mechatronics, machine dynamics, crashworthiness, biomechanics, artificial intelligence, and system identification if they involve or contribute to the field of Multibody System Dynamics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信